NCT05275868 is a Phase 1 clinical trial of MGY825 in Non-small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05275868?

NCT05275868 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05275868?

Interventions in NCT05275868: MGY825.

What condition does NCT05275868 study?

NCT05275868 studies Non-small Cell Lung Cancer.

Is NCT05275868 still recruiting?

NCT05275868 is currently terminated. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT05275868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Terminated Phase 1 Last updated 10 November 2025

What this trial tests

Phase 1 trial testing MGY825 in Non-small Cell Lung Cancer in 41 participants. Terminated before completion.

Timeline

5 October 2022

Primary endpoint
13 October 2025

13 October 2025

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	5 October 2022
Primary completion	13 October 2025
Estimated completion	13 October 2025
Sites	15 locations across Japan, Germany, South Korea, Switzerland, United States, Spain

Drugs / interventions tested

MGY825 — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

The Cancer Antioxidant Regulation System in Therapeutic Resistance.
Gu X, Mu C, Zheng R, Zhang Z, et al · · 2024 · cited 30× · PMID 39061847 · DOI 10.3390/antiox13070778
The Crosstalk between Autophagy and Nrf2 Signaling in Cancer: from Biology to Clinical Applications.
Shan C, Wang Y, Wang Y. · · 2024 · cited 27× · PMID 39664581 · DOI 10.7150/ijbs.103187
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations.
Paredes R, Borea R, Drago F, Russo A, et al · · 2025 · cited 8× · PMID 40764107 · DOI 10.1136/jitc-2025-012288
Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies.
Tanaka I, Koyama J, Itoigawa H, Hayai S, et al · · 2023 · cited 7× · PMID 37675220 · DOI 10.3389/fonc.2023.1249237
NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting.
Panda H, Rowland NG, Krall CM, Bowman BM, et al · · 2025 · cited 6× · PMID 40946102 · DOI 10.1038/s41388-025-03560-4
Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies.
Li Y, Ladd Z, Xiong Z, Bui-Linh C, et al · · 2025 · cited 4× · PMID 40507333 · DOI 10.3390/cancers17111853
STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer.
Kulkarni AA, Rock A, Lee M, Reyes A, et al · · 2026 · PMID 42187558 · DOI 10.3390/curroncol33050241

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05275868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05275868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing